Skip to main content
Equibles

Vasant Narasimhan

CEO

Novartis AG (NVS)

Equibles does not estimate personal net worth.

Get an email with a short summary when Novartis AG publishes a filing, an earnings call transcript or a press release.

Get NVS alerts

About Vasant Narasimhan

Vasant Narasimhan is recorded as CEO at Novartis AG (NVS). Vasant Narasimhan has spoken on 6 earnings calls across 1 company, most recently for Novartis AG on October 27, 2026. Novartis AG is classified in the Drug Manufacturers - General industry within the Healthcare sector.

Vasant Narasimhan on recent calls

“So, in the quarter, although one second, we're just getting our slides moving here. In the quarter, Novartis delivered sales growth and core margin expansion. And that supported an upgrade to our full year 2026 bottom line guidance.”
CEO, Q3 FY2026 Earnings conference call (announced in 6-K) ·
“So if we go to slide four, As you saw this morning, we delivered a strong start to the year across our priority brands and launches, which is really where our focus is at the moment.”
CEO, Novartis Q1 2026 Results Release ·
“With me in the room are Harry Kirsch, our Chief Financial Officer, and Mukul Mehta, our Chief Financial Officer-designate, who will be taking over for Harry in mid-March.”
CEO, Novartis AG Q4 FY2025 Earnings Call ·
“Novartis showed solid sales and core operating income growth, and we reached important pipeline milestones through the third quarter. Sales increased by 7%, and core operating income also rose by 7%, resulting in a core margin of 39.3%.”
CEO, Novartis AG Q3 FY2025 Earnings Call ·
“As we look at Slide 4, Novartis has once again posted a strong quarter, with double-digit sales growth and core margin expansion leading to an upgrade in our full-year guidance for 2025.”
CEO, Novartis AG Q2 FY2025 Earnings Call ·

Affiliation history

Company network

Recent activity